Clinical Trials
92 trialsPerioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma
Emory University
Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer
H. Lee Moffitt Cancer Center and Research Institute
A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer
National Institutes of Health Clinical Center (CC)
Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)
Dana-Farber Cancer Institute
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
Elevation Oncology
A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
National Institutes of Health Clinical Center (CC)
Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
Dana-Farber Cancer Institute
MK-6482-013
Merck Sharp & Dohme LLC
Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC)
M.D. Anderson Cancer Center
SPIRIT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Contrast-Enhanced Ultrasound for Kidney Cancer Subtyping and Staging
UNC Lineberger Comprehensive Cancer Center
Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer
University of Nebraska
IO-PAZ
Novartis
Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma
Eastern Cooperative Oncology Group
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
Eastern Cooperative Oncology Group
A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer
National Institutes of Health Clinical Center (CC)
CANTATA
Calithera Biosciences, Inc
UW17104
University of Wisconsin, Madison
Cabozantinib for Advanced Urothelial Cancer
National Institutes of Health Clinical Center (CC)
Tretinoin Plus Interferon Alfa in Treating Patients With Metastatic Kidney Cancer
Weill Medical College of Cornell University
Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer
Brown University
Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)
M.D. Anderson Cancer Center
High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer
University of Texas Southwestern Medical Center
PrE0801
PrECOG, LLC.
Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma
M.D. Anderson Cancer Center
Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer
Rutgers, The State University of New Jersey
RADVAX
University of Texas Southwestern Medical Center
Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma
Dana-Farber Cancer Institute
Neoadjuvant Clinical Trial to Evaluate the Efficacy of Bevacizumab for Renal Cell Carcinoma
M.D. Anderson Cancer Center
Bortezomib in Treating Patients With Metastatic Kidney Cancer
Jonsson Comprehensive Cancer Center
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy
Masonic Cancer Center, University of Minnesota
Cryotherapy and GM-CSF in Treating Patients With Lung Metastases or Primary Lung Cancer
Barbara Ann Karmanos Cancer Institute
Carfilzomib in Refractory Renal Cell Carcinoma (RCC)
M.D. Anderson Cancer Center
Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)
M.D. Anderson Cancer Center
Study of IL2 in Combination With Zoledronic Acid in Patients With Kidney Cancer
University of Wisconsin, Madison
CATChEz
Novartis
Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers
National Institutes of Health Clinical Center (CC)
Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney
Case Comprehensive Cancer Center
Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer
National Institutes of Health Clinical Center (CC)
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
Washington University School of Medicine
Phase II Study of Vandetanib in Individuals With Kidney Cancer
National Institutes of Health Clinical Center (CC)
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
Amgen
Gemcitabine and Irinotecan in Treating Patients With Locally Advanced Unresectable or Metastatic Kidney Cancer
Medical University of South Carolina
PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer
Medical University of South Carolina
DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC
Dartmouth-Hitchcock Medical Center
Interleukin-2 in Metastatic Kidney Cancer
Western Regional Medical Center
Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma
Dana-Farber Cancer Institute
ASPEN
Duke University
Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer
OHSU Knight Cancer Institute
Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer
National Institutes of Health Clinical Center (CC)